可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Kolodgie FD, Burke AP, Skorija KS,et al.Lipoproteinassociated phospholipase A2 protein expression in the natural progression of humam coronary atherosclerosis[J].Arterioscler Thromb Vasc Biol,2006,26(11):2523-2529.
[2] Tsimihodimos V, Kakafika A, Tambaki AP,et al.Fenofibrate induces HDLassociated PAFAH but attenuates enzyme activity associated with apoBcontaining lipoproteins[J].J Lipid Res,2003,44(5):927-934.
[3] Ishihara M, Iwasaki T, Nagano M,et al.Functional impairment of two novel mutations detected in lipoproteinassociated phospholipase A2(LpPLA2) deficiency patients[J].J Hum Genet,2004,49(6): 302-307.
[4] Abuzeid AM, Hawe E, Humphries SE,et al.Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe[J]. Atherosclerosis,2003,168(2): 283-288.
[5] Oei HH,van der Meer IM,Hofman A,et al.Lipoproteinassociated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study[J].Circulation,2005,111(5):570-575.
[6] Ballantyne CM,Hoogeveen RC,B ang H,et al. Lipoproteinassociated phospholipase A2, highsensitivity Creactive protein, and risk for incident coronary heart disease in middleaged men and women in the Atherosclerosis Risk in Communities (ARIC) study[J].Circulation,2004 ,109(7):837-842.
[7] Brilakis ES, McConnell JP, Lennon RJ,et al. Association of lipoproteinassociated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at followup[J].Eur Heart J,2005,26(2):137-144.